Papers, grouped by topic

Design and analysis of randomized clinical trials with average hazard: practical guidance and tools for implementation

Horiguchi M, Tian L, Hattori S, Uno H. Statistics in Medicine.

DOI ↗ PubMed ↗

A novel stratified analysis method for testing and estimating overall treatment effects on time-to-event outcomes using average hazard with survival weight

Qian Z, Tian L, Horiguchi M, Uno H. Statistics in Medicine.

DOI ↗ PubMed ↗

Assessing delayed treatment benefits of immunotherapy using long-term average hazard: a novel test/estimation approach

Horiguchi M, Tian L, Kehl KL, Uno H. Lifetime Data Analysis.

DOI ↗ PubMed ↗

Comparative effectiveness research with average hazard for censored time-to-event outcomes: simulation study and application to observational data

Xiong H, Connors J, Schrag D, Uno H. BMC Medical Research Methodology.

DOI ↗ PubMed ↗

Regression models for average hazard

Uno H, Tian L, Horiguchi M, Hattori S, Kehl KL. Biometrics 80(2):ujae037.

DOI ↗ PubMed ↗

Ratio and difference of average hazard with survival weight: new measures to quantify survival benefit of new therapy

Uno H, Horiguchi M. Statistics in Medicine 42(7):936–952.

DOI ↗ PubMed ↗

On sample size determination for augmented tests based on restricted mean survival time in randomized clinical trials

Hattori S, Uno H. Biometrical Journal.

DOI ↗ PubMed ↗

On assessing survival benefit of immunotherapy using long-term restricted mean survival time

Horiguchi M, Tian L, Uno H. Statistics in Medicine 42(8):1139–1155.

DOI ↗ PubMed ↗

A flexible and coherent test/estimation procedure based on restricted mean survival times for censored time-to-event data in randomized clinical trials

Horiguchi M, Cronin AM, Takeuchi M, Uno H. Statistics in Medicine 37(15):2307–2320.

DOI ↗ PubMed ↗

Alternatives to hazard ratios for comparing the efficacy or safety of therapies in noninferiority studies

Uno H, Wittes J, Fu H, Solomon SD, Claggett B, Tian L, Cai T, Pfeffer MA, Evans SR, Wei LJ. Annals of Internal Medicine 163(2):127–134.

PubMed ↗

Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis

Uno H, Claggett B, Tian L, Inoue E, Gallo P, Miyata T, Schrag D, Takeuchi M, Uyama Y, Zhao L, Skali H, Solomon S, Jacobus S, Hughes M, Packer M, Wei LJ. Journal of Clinical Oncology 32(22):2380–2385.

PubMed ↗

A versatile test for equality of two survival functions based on weighted differences of Kaplan–Meier curves

Uno H, Tian L, Claggett B, Wei LJ. Statistics in Medicine 34(28):3680–3695.

DOI ↗ PubMed ↗

Statistical test/estimation methods used in contemporary phase III cancer randomized controlled trials with time-to-event outcomes

Uno H, Horiguchi M, Hassett MJ. The Oncologist 25(2):91–93.

DOI ↗ PubMed ↗

Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology

Horiguchi M, Hassett MJ, Uno H. Clinical Trials 17(6):597–606.

DOI ↗ PubMed ↗

How do the accrual pattern and follow-up duration affect the hazard ratio estimate when the proportional hazards assumption is violated?

Horiguchi M, Hassett MJ, Uno H. The Oncologist 24(7):867–871.

DOI ↗ PubMed ↗

A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival data

Uno H, Tian L, Cai T, Kohane IS, Wei LJ. Statistics in Medicine 32(14):2430–2442.

PubMed ↗

Graphical procedures for evaluating overall and subject-specific incremental values from new predictors with censored event time data

Uno H, Cai T, Tian L, Wei LJ. Biometrics 67(4):1389–1396.

PubMed ↗

On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data

Uno H, Cai T, Pencina MJ, D'Agostino RB, Wei LJ. Statistics in Medicine 30(10):1105–1117.

DOI ↗ PubMed ↗

Evaluating prediction rules for t-year survivors with censored regression models

Uno H, Cai T, Tian L, Wei LJ. Journal of the American Statistical Association 102(478):527–537.

DOI ↗

Decomposing variations on cluster level for binary outcomes in application to cancer care disparity studies

Uno H, Tramontano AC, Punglia RS, Hassett MJ. Health Services Research.

DOI ↗ PubMed ↗

Predictors of recurrent venous thromboembolism and major bleeding in patients with cancer: a secondary analysis of the CANVAS trial

Uno H, Xiong H, Cronin C, Schrag D, Connors JM. Thrombosis Research.

DOI ↗ PubMed ↗

Biomarkers in oncology: complexities in biomarker-driven studies and statistical analysis

Uno H, Horiguchi M. JCO Precision Oncology.

DOI ↗ PubMed ↗

Use of cancer-directed therapy at the end of life among adolescents and young adults

Mack JW, Cernik C, Xu L, Laurent CA, Fisher L, Cannizzaro N, Munneke J, Cooper RM, Lakin JR, Schwartz CM, Casperson M, Altschuler A, Wiener L, Kushi LH, Chao CR, Uno H. Journal of the National Cancer Institute.

DOI ↗ PubMed ↗

Determining the time of cancer recurrence using claims or electronic medical record data

Uno H, Ritzwoller DP, Cronin AM, Carroll NM, Hornbrook MC, Hassett MJ. JCO Clinical Cancer Informatics.

DOI ↗ PubMed ↗